Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|April 26, 2022
A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric PopulationManfred Wargenau, Sibylle Reidemeister, Ingrid Klingmann, et al.European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 10, 2023
Patient-centric drug product development: Acceptability across patient populations - Science and evidenceSven Stegemann, Viviane Klingmann, Sibylle Reidemeister, et al.Pharmaceutics|July 30, 2025
Survey Study to Identify the Maximum Acceptable Numbers of 2 mm and 3 mm Mini-Tablets for Short-, Middle-, and Long-Term Treatments in Acutely and Chronically Sick Children of Different Age Groups Below 18 YearsManfred Wargenau, Eva Mutzke, Lucas-Sebastian Spitzhorn, et al.Research Involvement and Engagement|November 30, 2023
Young patients' involvement in a composite endpoint method development on acceptability for paediatric oral dosage formsSibylle Reidemeister, Begonya Nafria Escalera, Daniel Marín, et al.Pharmaceutics|April 27, 2024
Questionnaire Study to Investigate the Preferences of Children, Parents, and Healthcare Professionals for Different Formulations of Oral Medicinal ProductsManfred Wargenau, Felicitas Baase, Kristin Eckardt, et al.Frontiers in Pharmacology|September 3, 2024
Validating a composite endpoint for acceptability evaluation of oral drug formulations in the pediatric population: a randomized, open-label, single dose, cross-over studyJuliane Münch, Anna Lena Schwarzwälder, Carolin Kloft, et al.Pharmaceutics|June 28, 2023
Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over StudyJuliane Münch, Isabelle Sessler, Hans Martin Bosse, et al.Journal of Medicinal Chemistry|February 18, 2010
1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonistsLeo Widler, Eva Altmann, René Beerli, et al.Pageof 1